Omeros Corporation
$ 16.57
5.47%
29 Dec - close price
- Market Cap 1,174,820,000 USD
- Current Price $ 16.57
- High / Low $ 16.64 / 14.43
- Stock P/E N/A
- Book Value -3.15
- EPS -2.13
- Next Earning Report 2026-03-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -5.76 %
- 52 Week High 17.65
- 52 Week Low 2.95
About
Omeros Corporation is a Seattle-based biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for significant unmet medical needs. The company boasts a diverse pipeline, including protein and small molecule therapies that target inflammation, complement-mediated diseases, and central nervous system disorders. By focusing on orphan indications, Omeros is well-positioned for growth, enhancing patient care and establishing itself as a pivotal player in the biopharmaceutical space, committed to delivering advanced treatment solutions.
Analyst Target Price
$28.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-07 | 2024-08-07 | 2024-05-15 | 2024-03-26 | 2023-11-09 | 2023-08-09 | 2023-05-09 | 2023-03-13 |
| Reported EPS | -0.34 | -0.43 | -0.5408 | -0.55 | -0.64 | -0.97 | -0.63 | -0.15 | -0.6 | -0.59 | -0.54 | 2.05 |
| Estimated EPS | -0.45 | -0.46 | -0.58 | -0.71 | -0.7 | -1.14 | -0.58 | -0.55 | -0.62 | -0.57 | -0.56 | -0.57 |
| Surprise | 0.11 | 0.03 | 0.0392 | 0.16 | 0.06 | 0.17 | -0.05 | 0.4 | 0.02 | -0.02 | 0.02 | 2.62 |
| Surprise Percentage | 24.4444% | 6.5217% | 6.7586% | 22.5352% | 8.5714% | 14.9123% | -8.6207% | 72.7273% | 3.2258% | -3.5088% | 3.5714% | 459.6491% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-03 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.4549 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OMER
2025-12-29 12:09:05
Omeros Corporation announced FDA approval of YARTEMLEA for treating TA-TMA. This marks the first approved treatment for TA-TMA in adults and children 2+ years, demonstrating high complete response rates and favorable survival rates in trials. The U.S. launch is planned for January 2026.
2025-12-29 10:57:00
Omeros Corporation announced FDA approval for YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and pediatric patients aged two and older. This marks the first and only approved therapy for TA-TMA, a life-threatening condition. The approval is a significant milestone for Omeros, transforming it into a revenue-generating company with its first commercial product, and is supported by strong clinical results and a favorable safety profile.
2025-12-27 00:08:50
Omeros Corporation has rescheduled its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The call will now take place on Wednesday, January 7, 2026, at 4:30 p.m. Eastern Time, allowing broader participation and accommodating holiday schedules. YARTEMLEA® is a monoclonal antibody that inhibits the lectin pathway of complement, providing a targeted treatment for this severe and often fatal complication.
2025-12-26 23:08:50
Omeros Corporation has rescheduled its conference call to discuss the FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The call will now occur on Wednesday, January 7, 2026, at 4:30 p.m. Eastern Time, to accommodate holiday schedules and allow for broader participation. YARTEMLEA® is also under review by the European Medicines Agency, with a decision expected in mid-2026.
2025-12-26 16:08:50
Omeros (NASDAQ:OMER) experienced a significant trading volume increase of 3% on Friday, with approximately 1.78 million shares traded, though the stock saw a 5.1% decline. Despite mixed analyst ratings, the consensus remains a "Moderate Buy" with a target price of $33.67, and the company recently beat EPS estimates even while remaining unprofitable. Several hedge funds have also adjusted their positions in Omeros, indicating ongoing investor interest.
2025-12-26 12:08:46
Omeros Corp (Nasdaq: OMER) shares surged 75.5% after the US FDA approved its drug Yartemlea (narsoplimab-wuug) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Yartemlea is the first and only approved lectin pathway inhibitor for this often-fatal complication. The global market for complement-mediated thrombotic microangiopathy therapies reached $2.14 billion in 2024 and is projected to grow with a CAGR of 10.7%.
